Gilead Sciences, Inc. vs Alliant Energy Corporation — how do they compare? Gilead Sciences, Inc. trades at $135.49 (market cap $168.35B), while Alliant Energy Corporation trades at $68.76 (market cap $17.78B). The key difference: Gilead Sciences, Inc. is far larger — about 9.5× Alliant Energy Corporation's market cap, and Alliant Energy Corporation pays the higher dividend (3.12%). Which is the better fit depends on your goals.
| GILD | LNT | |
|---|---|---|
Market Cap | $168.35B | $17.78B |
Sector | Health | Utilities |
52-Week High | $155.80 | $78.03 |
52-Week Low | $110.56 | $63.62 |
Enterprise Value | $191.42B | $29.88B |
Dividend Yield | 2.42% | 3.12% |
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →